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Obesity-induced liver inflammation can drive insulin resistance. HDL has anti-inflammatory 
properties so we hypothesized that low levels of HDL perpetuate inflammatory responses in 
the liver and that HDL treatment will suppress liver inflammation and insulin resistance. The 
aim of this study was to investigate the effects of lipid-free apoAI on hepatic 
inflammation and insulin resistance in mice. We also investigated apoAI as a component 
of reconstituted HDL (rHDLs) in hepatocytes to confirm results we observe in vivo.  To 
test our hypothesis, C57BL/6 mice were fed a high-fat diet (HFD) for 16-weeks and 
administered either saline or lipid-free apoAI. Injections of lipid-free apoAI twice a week for 
2- or 4- weeks with lipid-free apoAI resulted in: (i) improved insulin sensitivity associated 
with decreased systemic and hepatic inflammation; (ii) suppression of hepatic mRNA 
expression for key transcriptional regulators of lipogenic gene expression and; (iii) 
suppression of NF-B activation. Human hepatoma HuH-7 cells exposed to rHDLs showed 
suppressed TNF-α-induced NF-B activation, correlating with decreased NF-B target gene 
expression. We conclude that apoAI suppressed liver inflammation in HFD mice and 
improved insulin resistance via a mechanism that involves a downregulation of NF-B 
activation.  
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Hepatic inflammation can induce insulin resistance via an imbalance in the secretion 
of pro-inflammatory cytokines, subsequent to activation of inflammatory/oxidative 
transcription factors (1). A key transcription factor that mediates the inflammatory response 
in hepatocytes is nuclear factor-B (NF-B) (2, 3). Activated hepatic NF-B alone can drive 
insulin resistance as evidenced by the finding that transgenic expression of IB kinase, IKK-
, which increases NF-B activity, results in overt insulin resistance in mice fed a normal 
chow diet (4). Conversely, when heterozygous IKK-+/- mice expressing low levels of NF-B 
are fed a high-fat diet, or are crossed with ob/ob mice, they do not develop insulin resistance 
(5). Moreover, genetic manipulation to inhibit hepatic NF-B activity directly protects 
against insulin resistance in response to a high-fat diet in mice (4). Such findings provide 
strong evidence that the liver is a primary site of inflammatory action that causes insulin 
resistance and that NF-B is a central pathogenic factor underlying inflammation-induced 
insulin resistance.  
NF-B activation increases the secretion of a number of pro-inflammatory cytokines, 
including IL-6, TNF-α and IL-1 (1). NF-B activation involves a complex series of 
signalling events that begins with activation of the IB kinase complex that, in turn, 
phosphorylates inhibitor B (IB) (6, 7).  IB is an inhibitor protein of NF-B that binds to 
NF-B, sequestering it in the cytoplasm (8). However, once phosphorylated, IB is targeted 
for ubiquitination and subsequent degradation, leaving NF-B free to translocate to the 
nucleus and initiate transcription of target genes (9).  
High density lipoproteins (HDLs) have potent anti-inflammatory effects (10, 11). We 
have previously reported that pre-treatment of human coronary artery endothelial cells 
(HCAEC) with HDLs inhibits TNF-induced NF-B activation (12). In addition, injections 
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of human apolipoprotein A-I (apoAI) (the major HDL protein) into rabbits inhibits vascular 
inflammation (10). HDL levels are reportedly low in subjects with insulin resistance (13) so 
this led us to question whether raising HDL may improve insulin resistance by targeting the 
heightened hepatic inflammatory state. We show that injections of lipid-free apoAI decrease 
both hepatic and systemic cytokine levels, suppress hepatic NF-B activation and improve 
insulin sensitivity in high-fat fed C57BL/6 mice. Moreover, we demonstrate that apoAI-
containing reconstituted HDLs (rHDLs) mediate their anti-inflammatory effects in cultured 




MATERIALS AND METHODS 
Preparation of lipid-free apolipoprotein A-I (apoAI) and discoidal reconstituted HDLs 
(rHDLs) 
  HDLs were isolated from pooled human plasma (Gribbles Pathology, Adelaide, SA, 
Australia) by sequential ultracentrifugation in the 1.063-1.21 g/ml density range. Lipid-free 
apoAI was then isolated from HDL as previously described (14). Discoidal rHDLs containing 
apoAI complexed to 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphatidylcholine (PLPC; 
Avanti Polar Lipids, Alabaster, Alabama, USA) were prepared by the cholate dialysis method 
(15). The PLPC:apoAI molar ratio was 100:1. Immediately before use in experiments, lipid-
free apoAI or rHDLs preparations were dialysed extensively against endotoxin-free 
phosphate buffered saline (PBS; Sigma-Aldrich, Castle Hill, NSW, Australia)(pH 7.4).  
 
Animal Model  
 Five week old C57BL/6 male mice purchased from Monash Animal Services 
(Monash University, VIC, Australia) were housed at the Heart Research Institute Biological 
Services facility (Sydney, NSW, Australia) and kept at a temperature of 21C  2C on a 
12:12 h light/dark cycle. All experiments were approved by the South Western Sydney Area 
Health Service Animal Welfare Committee. At 6 weeks of age, the mice were randomised 
into four groups: (1) Control mice (n=10) were fed a standard chow diet (StD:14.3 MJ/kg; 
65% of energy from carbohydrate (wheat, barley, lupins); 12% from fat (mixed vegetable 
oils, canola oil); 23% from protein (soya meal, fish meal); Specialty Feeds, Glen Forrest, 
WA, Australia); (2) Mice (n=10) fed a high-fat diet (HFD: 19.4 MJ/kg; 43% of energy from 
carbohydrate – sucrose, cellulose, wheat starch; 40% from fat-clarified butter (Ghee), 
cholesterol, 17% from protein (casein); SF00-219, Specialty Feeds) ad libitum for 16 weeks 
total. At 18 weeks of age and 13 weeks of HFD this subset of mice received endotoxin-free 
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PBS (vehicle control) by tail vein injection twice weekly for the last 4 weeks of the diet; (3) 
Mice (n=10) fed a HFD ad libitum for 16 weeks total. At 18 weeks of age and 13 weeks of 
HFD this subset of mice received apoAI by tail vein injection twice weekly for the last 4 
weeks of the diet and; (4) Mice (n=10) fed a HFD ad libitum for 16 weeks total. At 20 weeks 
of age and 15 weeks of HFD this subset of mice received apoAI by tail vein injection twice 
weekly for the last 2 weeks of the diet. ApoA-I was administered at a dose of 8 mg/kg. 
Animals were sacrificed at 24 hours after their final injection by right atrium exsanguination 
after methoxyflurane (Medical Developments International, Springvale, VIC, Australia) 
anaesthesia. Blood samples were centrifuged (1,000 x g for 10 min) and the subsequent 
serum fraction collected and stored at –20C. Liver tissue was rapidly excised, snap frozen in 
liquid nitrogen and stored at –80C.  
 
Glucose-, insulin tolerance and pyruvate challenge tests, fasting serum 
triglyceride, cytokine and insulin measurements.   
 At the end of the study, an intraperitoneal glucose tolerance test (IPGTT), an 
intraperitoneal insulin tolerance test (IPITT) and a pyruvate challenge test were performed in 
overnight fasted mice. Blood samples were obtained from the tail tip at the indicated times 
and glucose levels were measured using a glucometer (Accu-Chek, Roche, Castle Hill, NSW, 
Australia). The doses used during these tests were glucose at 1 g/kg body weight, insulin at 
0.75 IU/kg body weight and pyruvate at 2 g/kg body weight for IPGTT, IPITT and pyruvate 
challenge test, respectively. Serum triglyceride levels were measured with triglyceride 
reagent (Roche Diagnostics, Castle Hill, NSW, Australia). Serum cytokine levels were 
determined using a mouse Bioplex Kit (Bio-Rad, Hercules, CA, USA). Insulin levels were 
measured using an enzyme-linked immunosorbent assay (Crystal Chem, Downers Grove, IL, 
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USA). The homeostatic model assessment of insulin resistance (HOMA-IR) was determined 
for each mouse (4).  
 
Intrahepatic neutral lipid accumulation assay 
 The level of neutral lipids (triglyceride plus cholesterol esters) accumulated in the 
liver was determined by measurement of Oil Red-O of tissue extracts by quantitative assay 
(16). Briefly, frozen liver tissue (100 mg) was homogenized and incubated with an Oil Red-O 
solution (0.15% Oil Red-O, 0.4% dextrin) for 60 min. The samples were washed with 60% 
isopropanol to remove excess dye and the dye incorporated into lipid was then extracted with 
99% isopropanol and quantified by measurement of absorbance at 520 nm (16). 
  
Cell culture 
 A human hepatoma cell line (HuH-7; Health Science Research Resources Bank, 
Osaka, Japan) were cultured in DMEM/F12 medium (Sigma-Aldrich) with 10% FBS at 37C 
in 5% CO2. Unless otherwise stated, HuH-7 cells were pre-incubated for 16 hours with 
rHDLs (final apoAI concentration, 16 mol/l or 0.45 mg/ml), PBS (control), sodium 
salicylate (5 mmol/l, Sigma-Aldrich) or the IKK inhibitor, Wedelolactone (8 mmol/l, 
Calbiochem, Gibbstown, NJ, USA) then stimulated with TNF- (1 ng/mL) for 24 hours. For 
some cells, after the 16-hour incubation, the rHDL-containing medium was removed and 
cells were washed twice with PBS before fresh medium supplemented with TNF-α (1 ng/mL) 
was added for 24 hours. Non-TNF--stimulated, PBS treated cells acted as controls. 
 
Cholesterol depletion and repletion 
Cholesterol depletion was performed by incubating HuH-7 cells with 1.5% methyl-β-
cyclodextrin for 1 hour at 37°C. To perform cholesterol repletion, cholesterol (0.4 
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mg/ml) was mixed by vortexing with methyl-β-cyclodextrin (10%) at a 1:20 ratio at 
40°C.  Following incubation of HuH-7 cells with rHDL for 16 hour, cholesterol repletion 
was performed by the addition of the cholesterol/cyclodextrin solution diluted at 1:25 
for another hour.  
 
Lactate dehydrogenase (LDH) cell viability assay  
 HuH-7 cells were incubated for 40 hours with rHDLs (final apoAI concentration, 16 
µmol/l or 0.45 mg/ml), PBS (control) or sodium salicylate (5 mmol/l, Sigma-Aldrich). 
Following incubation, cell media was collected and stored on ice. The cells were then washed 
with PBS and lysed in 1 mL of water for 20 min at 4C. After centrifugation (1000 x g, 5 
min) to pellet and remove cell debris, 10 µL cell lysate or cell media were incubated with 200 
µL of 0.15 mg/mL NADH and 2.5 mmol/l sodium pyruvate PBS working reagent. The 
absorbance at 340 nm was determined at 5 min intervals for 35 min (Tecan Sunrise; Tecan 
Group Ltd, Mannedorf, Switzerland). Viability was calculated from the relative activity of 
LDH measured for the media versus total activity (17).  
 
Transient cell transfections and luciferase measurements  
 HuH-7 cells were transfected with an NF-B-luciferase reporter vector (Promega 
Corporation, Madison, WI, USA) together with a transfection control plasmid, pRL-TK 
(Promega) using Effectene (Qiagen, Hilden, Germany) (18). Transfected cells were pre-
incubated with rHDLs (final apoAI concentration, 16 µmol/l or 0.45 mg/ml) then stimulated 
with 1 ng/mL TNF- (rHDL+TNF). A subset of transfected cells were pre-incubated with 
rHDLs but the rHDLs were removed from the culture media prior to activation with TNF- 
(rHDL//TNF). After treatment, cells were washed with PBS and then lysed with passive 
lysis buffer (Promega). Samples were collected, centrifuged to remove cell debris and then 
10 
 
assayed for luciferase and renilla activity using the Dual-Luciferase Reporter System 
(Promega). Measurements were obtained using the Fluoroskan Ascent FL luminometer 
(Thermo Labsystems, Waltham, MA, USA).  
 
IB kinase (IKK) assay  
 HuH-7 cells were pre-treated with rHDLs (final apoAI concentration, 16 µmol/l or 
0.45 mg/ml) or PBS, then stimulated with TNF- (1 ng/ml) for 15 min. The cells were lysed 
in RIPA lysis buffer containing 1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, 150 
mmol/l NaCl, 50 mmol/l Tris, pH 8 and a protease inhibitor cocktail (Sigma-Aldrich). The 
protein lysate (10 g) was incubated with 2 mmol/l ATP and 10 g IKK substrate peptide 
(Millipore, Billerica, MA, USA) in reaction buffer (8 mmol/l MOPS, pH 7, 0.2 mmol/l 
EDTA-Na2) at room temperature for 90 min. Kinase-Glo reagent (50 l; Promega) was then 
added to the reaction mixture, incubated at room temperature for 10 min and the luminescent 
signal was measured on a Fluoroskan Ascent FL (Thermo Labsystems).  
 
IB Assay  
 Whole cell protein lysate was extracted from HuH-7 cells in RIPA lysis buffer as 
described for the IKK assay. The protein lysate (100 mg) was assayed for IB- levels using 
the PathScan Phospho-IκBα and Total IB enzyme-linked immunosorbent assay (Cell 
Signaling Technology, Danvers, MA, USA).  
 
NF-B nuclear translocation assay  
 Nuclear proteins were extracted from HuH-7 cells or liver samples using the 
NucBuster protein extraction kit (Merck & Co., Whitehouse Station, NJ, USA). Nuclear 
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proteins (100 g) were assayed using the NF-B NoShift transcription factor assay kit 
(Merck & Co.).  
 
Human NF-B Target Gene Array Analysis 
            Total RNA was isolated from HuH-7 cells using TRI reagent (Sigma-Aldrich). 
Biotin-labelled cDNA probes were prepared from 10 g of total RNA using AMV reverse 
transcriptase (Promega) and biotin dUTP. The cDNA probes were then hybridized to the 
TranSignal NF-B Target Gene array (Panomics, Santa Clara, CA, USA). Direct 
chemiluminescence imaging was performed using the ChemiDoc XRS (Bio-Rad, Hercules, 
CA, USA) imaging system. Quantity One software (Bio-Rad) was used for pairwise 
comparative gene expression after signal intensities were converted to a ratio adjusted for 
background and reference gene expression. The array reproducibility was verified by RT-
qPCR for genes of interest. 
 
Isolation of total mRNA and analysis by RT-qPCR 
 Total RNA was extracted from HuH-7 cells or liver samples using TRI reagent 
(Sigma-Aldrich) and the concentration normalized to 100 ng/L using the SYBR Green II 
assay (Molecular Probes, Invitrogen, Melbourne, Australia). RNA integrity was determined 
with the Experion system (Bio-Rad). cDNA was reverse transcribed from total RNA (100 ng) 
using iSCRIPT (Bio-Rad). Gene expression (see ESM Table I for primer sequences) was 
amplified by PCR in reaction mixtures containing 12 pmol primers and iQ SYBR Green 
Supermix. Amplification was performed in a Bio-Rad iQ5 thermocycler using the following 
protocol: 95C for 30 sec, 60C for 30 sec and 72C for 30 sec. Relative change in mRNA 
gene expression was determined by the CT approach (19), using β-2-microglobulin (β2M) 
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levels as the reference gene for human samples or transcription factor IID (Tbp) for mouse 
samples.  
 
Statistical Analysis  
 Data are expressed as meanSEM. Significant differences in treatments were 
determined by one-way ANOVA with Bonferroni’s post-test analysis. PRISM software was 






ApoAI improves glucose tolerance, insulin sensitivity and hepatic glucose metabolism in 
HFD-fed mice  
HFD-fed C57BL/6 mice had a 14-15 g (p<0.05) increase in body weight compared to 
StD-fed mice over the 16-week study period (Fig. 1A). The increase in body weight was 
associated with increased serum triglyceride, hepatic neutral lipid (triglyceride plus 
cholesterol esters) levels (ESM Fig. IIIA,B p<0.01 for both) and key transcriptional 
regulators of lipogenic gene expression in the liver sterol regulatory element binding protein 
1 (SREBP-1) and carbohydrate responsive element–binding protein (ChREBP)(p<0.001; Fig. 
1B,C). The HFD-induced increase in body weight was not affected by the apoAI treatments, 
however suppressed the HFD-induced increase in serum triglyceride, hepatic neutral lipid 
(triglyceride plus cholesterol esters) levels, SREBP-1 and ChREBP levels (ESM Fig. IIIA, B 
and Fig. 1B, C, respectively).  
Insulin resistance as measured by the homeostasis model assessment-IR (HOMA-IR, 
(1)) was 12-fold higher in the HFD-fed C57BL/6 mice than in the control animals (ESM Fig. 
I). Both 2 and 4 weeks of treatment with apoAI reduced the HOMA-IR in the HFD-fed 
animals by 2.81±0.97-fold and 2.85±0.4-fold, respectively (p<0.05 for both). HFD-fed mice 
displayed glucose intolerance, with levels of both fasting insulin (ESM Fig. IIA, p<0.05) and 
glucose (ESM Fig. IIB, p<0.05) being increased by 3.2±0.5-fold and 1.44±0.7-fold, 
respectively. Treatment with apoAI for 2 and 4 weeks significantly reduced fasting insulin 
and glucose levels. These results were consistent with the apoAI treatment improving IPGTT 
and IPITT (Fig. 2A-D). ApoAI treatment also improved hepatic glucose metabolism as 
determined by the pyruvate challenge assay (Fig. 2E,F). This was associated with an apoAI-
induced suppression of mRNA levels encoding the rate-limiting enzymes in gluconeogenesis, 
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phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) (Table 
1).   
 
Cytokine expression following ApoAI-treatments  
Serum cytokine levels were measured to assess systemic inflammation. HFD-fed mice 
had elevated serum concentrations of TNF- (p<0.05), IL-6 (p<0.001) and IFN- (p< 0.001), 
compared to StD-fed mice (Fig. 3). ApoAI treatment for both 2 and 4 weeks reduced serum 
levels of IL-6 by 94±0.13% (p<0.01) and 96±9% (p<0.01), respectively. Similarly, the 
apoAI-treatments significantly reduced serum levels of IFN- and TNF- by 36-58±9-19% 
(p<0.05).  
Table 1 shows that treatment with apoAI significantly decreased TNF-, IL-6, IFN-, 
IL-1 and SAA1 hepatic mRNA levels in the HFD mice. Mice consuming the HFD had an 
increased number of macrophages (Kupffer cells) in the liver as demonstrated by an increase 
in mRNA levels of the macrophage-specific genes CD68 and F4/80. Treatment of the HFD 
mice with apoAI for 2 or 4 weeks decreased the hepatic expression of both CD68 and F4/80 
(Table 1).  
 
ApoAI- suppressed activated NF-B levels 
NF-B is the key regulator of TNF-, IL-6, IFN-, IL-1 and SAA1 gene expression 
in the liver (20, 21). As shown in Fig. 4, the HFD-fed mice had a 30±3% (p<0.05) increase in 
hepatic nuclear NF-B levels relative to levels in the StD-fed mice. Treatment with apoAI 
decreased NF-B levels and, in the animals treated with apoAI for 4 weeks, the NF-B 




We have previously shown that apoAI as a component of discoidal rHDLs suppressed NF-B 
activation through increased expression of DHCR24, and that this enzyme is at least, in part, 
responsible for mediating the anti-inflammatory effects of rHDLs in human coronary aortic 
endothelial cells (12). ESM Fig. IV shows there was no change in hepatic DHCR24 mRNA 
expression in HFD-fed mice treated with apoAI for 2 or 4 weeks.   
 
rHDLs suppressed classical NF-B signalling in cultured human hepatocytes 
The human transformed liver cell line (HuH-7) was transfected with an NF-B-
luciferase reporter vector, then pre-incubated for 16 hours with discoidal rHDLs (final apoAI 
concentration, 16 µmol/l or 0.45 mg/ml). After exposure to rHDLs, the HuH-7 cells were 
stimulated with TNF- for 5 hours to induce inflammation. Cells pre-treated with PBS alone 
before being activated with TNF- acted as positive controls. Fig. 5A shows that exposure to 
TNF- increased NF-B activation by 808% (p<0.0001), an effect that was abrogated in 
the cells pre-treated with rHDLs (rHDL+TNFα). The effect of rHDLs was not due to 
blockade of the TNF- receptor as the effects of the rHDLs was sustained even if the rHDLs 
were removed from the culture media prior to TNF- stimulation (rHDL//TNFα). Using an 
NF-B nuclear translocation assay, Fig. 5B confirms the reporter assay results with pre-
treatment with rHDLs decreasing TNF--induced nuclear NF-B levels.    
We next examined whether rHDLs (final apoAI concentration, 16 µmol/l or 0.45 
mg/ml) treatment decreased IKK activation thereby stopping IB degradation. As shown 
TNF- increased IKK activity by 160.7% (p<0.01; Fig. 5C), this effect was abrogated by 
rHDL treatment (p<0.05). Treatment with the rHDLs also effectively blocked IB 





rHDL anti-inflammatory effects are not via cholesterol mobilization  
The anti-inflammatory effects of rHDL may be due to rHDL-mediated cholesterol 
mobilization from the plasma membrane. Figure 6 shows cholesterol depletion by treatment 
with 1.5% methyl-β-cyclodextrin for 1 hour or cholesterol repletion with a 
cholesterol/cyclodextrin mixture (final concentration of cholesterol = 16 μg/ml) for another 
hour did not significantly affect the activation of NF-B compared to control. Similarly, 
incubation of HuH-7 cells with rHDL for 16 hours or rHDL for 16 hours followed by 
cholesterol repletion for another hour with the cholesterol/cyclodextrin mixture also had no 
effect on the activation of NF-B as measured by a NF-B nuclear translocation assay.  
 
rHDLs are more effective than 5 mmol/l salicylate at inhibiting TNF-induced NF-B 
activity 
Sodium salicylate suppresses hepatic NF-B activity and improves insulin sensitivity 
in C57BL/6 mice (22). We found that pre-treatment of the cells with rHDLs is as effective as 
5 mmol/l sodium salicylate in suppressing TNF--activated NF-B activation. HuH-7 cells 
were transfected with the NF-B-luciferase reporter vector and then exposed to rHDLs (final 
apoAI concentration, 16 μmol/l = 0.45 mg/ml) or 5 mmol/l sodium salicylate (S) for 16 hours 
prior to a 5 hour TNF- activation. Fig. 7A shows rHDLs suppressed TNF--induced NF-B 
activation to levels similar to those observed with both 5 mmol/l sodium salicylate and the 
IKK inhibitor, Wedelolactone. Additionally, unlike 5 mmol/l sodium salicylate, rHDL 
treatment had no effect on cell viability (Fig. 7B). 
 
rHDLs inhibit NF-B target gene expression 
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NF-B is a central mediator of the inflammatory response in many cell types (20, 21). 
Using a NF-B target gene macroarray, it was determined that pre-treatment with rHDLs 
decreased the expression of a number of target genes, including cytokines/chemokines (IL8, 
MCP1, PTX3, GRO1, SAA1), proteinase inhibitors (A1AT), cell differentiation and 
proliferation associated genes (GAL3, MAD3, TP53, PRG1), reactive oxygen stress 
associated genes (MNSOD, GSTP1) and cell adhesion molecules (LAMB2)(ESM Fig. V). The 






High fat feeding of mice induces systemic and hepatic inflammation, increases 
hepatic NF-B activation, impairs glucose tolerance and induces insulin resistance (4, 
23). The present study shows that intravenous infusion of apoAI into these animals 
reversed all of these changes. In vitro, TNF-α induced inflammation of hepatocytes  
resulted in increased IKK activity, increased phosphorylation of IB-α and increased 
activation of NF-B. Exposure of these activated hepatocytes to apoAI (as a component 
of rHDLs) reversed all of these changes.  
The present study is the first to show that administration of apoAI is able to 
improve glucose tolerance and insulin sensitivity in HFD-fed C57BL/6 mice. The 
proposed mechanism involves anti-inflammatory effects via suppression of hepatic NF-
κB activation. This mechanism is similar to that described for sodium salicylate in 
protecting against hepatic inflammatory and subsequently development of insulin 
resistance (4).  Insulin resistance remains hard to treat as to date there are a few 
targeted medicines. We have previously demonstrated that rHDLs (with apoAI as the 
main protein) have strong anti-inflammatory effects in endothelial cells – a key cell type 
in atherosclerosis (12). Given that preparations of HDLs are currently in clinical 
development as anti-atherogenic agents, a logical next step will be to test the ability of 
these preparations in protecting against the hepatic inflammation and insulin resistance 
that accompanies non-alcoholic fatty liver. 
In this study we showed that apoAI treatment, either independently or as part of 
a reconstituted HDL particle,  suppressed a number of inflammatory, oxidant and 
apoptotic stimuli via signalling through the canonical NF-κB pathway. In previous 
studies, we have shown that administration of apoAI at a dosage of 8mg/kg does not 
lead to a significant increase in the circulating HDL level (24) and, as such, the molecular 
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mechanism activated in vivo by an apoAI injection to mediate the anti-inflammatory effects 
on hepatic NF-B activation remains to be determined, although may involve upregulation of 
DHCR24 and other cellular protective enzymes. We have previously shown that apoAI as a 
component of discoidal rHDLs suppressed NF-B activation through increased 
expression of DHCR24 (a cellular protective enzyme) levels, and that this enzyme is at 
least, in part, responsible for mediating the anti-inflammatory effects of rHDLs in 
human coronary aortic endothelial cells (12). However, in the current study, there was 
no increase in DHCR24 expression, at least at the mRNA level, in the liver of apoAI-
treated mice so it is likely another mechanism is responsible for HDLs protection 
against NF-κB activation. One of the major protective properties of HDL revolves 
around its ability to promote cholesterol efflux. It has been shown in macrophages, 
endothelial cells and recently adipocytes (25–27) that the anti-inflammatory effects 
mediated by HDL is due, at least in part, to cholesterol efflux. However, in this study, we 
found that modulation of membrane cholesterol using methyl-β-cyclodextrin (depletes 
membrane cholesterol) or HDL had no effect on NF-κB activation suggesting that 
cholesterol efflux does not have a key role in the anti-inflammatory effects of HDL in 
hepatocytes. The underlying mechanism now needs to be interrogated further for a 
complete understanding.  
We have also shown that 2- and 4-weeks of apoAI treatment decreased 
expression of the gluconeogenesis-associated PEPCK and G6Pase, an effect that 
correlated with an improved response to the pyruvate challenge. Thus, in addition to 
the effects on insulin resistance, apoAI may decrease glucose output from the liver via 
suppression of gluconeogenesis, most likely through effects on NF-B.  
Improvement in systemic insulin resistance and glucose homeostasis as a result 
of apoAI treatment may be an additive consequence of effects on multiple organs 
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including the liver, pancreas, adipose tissue and skeletal muscle. We have previously 
reported that apoAI treatment of cultured pancreatic β-cells increased both the 
synthesis and secretion of insulin in the setting of both high and low glucose 
concentrations (28). In keeping with this finding, apoAI as a component of rHDL has 
also been shown to reduce plasma glucose levels in patients with type 2 diabetes, 
associated with an rHDL mediated increase in plasma insulin (28). ApoAI rHDL was 
shown to increase AMPK activity in skeletal muscle in type 2 diabetes patients (29) and 
that this was a key pathway to glucose reduction in these patients as increased AMPK 
induces increased glucose uptake by skeletal muscle cells. In a study of apoAI-
transgenic mice, rather than apoAI treatment, it was shown that adipose tissue 
inflammation induced by a high fat, high sucrose diet was ameliorated, relative to wild 
type mice, in keeping with reports that HDL and apoAI have anti-inflammatory effects 
on adipocytes (30).  A direct anti-obesity effect on apoAI and its mimetic peptide has 
also been recently reported whereby HDL treatment increased adipose tissue 
expenditure through attainment of brown adipocyte phenotype in white adipose tissue 
(31). Apolipoprotein A-I possesses an anti-obesity effect associated with increase of 
energy expenditure and up-regulation of UCP1 in brown fat. We now show that apoAI 
decreases liver inflammation by suppressing NF-B activation. It is likely that the 
profound ability of apoAI as a component of rHDL to improve insulin resistance is a 
combined effect on the liver, adipose tissue, pancreas and skeletal muscle. We suspect 
that apoAI-induced suppression of hepatic NF-B activation is central to the overall 
protective effect of apoAI on insulin resistance, a suggestion consistent with the 
observations of Shoelson et al who demonstrated that NF-B activation alone in the 
liver is sufficient to drive the onset of insulin resistance in mice (4).     
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A limitation of this study is that it was completed in a mouse model and 
therefore may not reflect what is clinically relevant in human subjects. However, recent 
findings in humans show that HDL-raising interventions were associated with an 
increase in insulin sensitivity in patients with type 2 diabetes (32). More direct evidence 
of HDL improving insulin resistance in humans was provided in a study showing 
infusion of rHDL particles increased increased plasma insulin levels, and decreased 
plasma glucose levels in type 2 diabetic subjects (29). Moreover, salsalate, a non-
acetylated salicylate, was used to treat patients with type 2 diabetes and in this study 
reduced HbA1c levels (33) thereby providing evidence for the hypothesis that an anti-
inflammatory approach could be used to treat insulin resistance and subsequent type 2 
diabetes. However, to date, the mechanisms by which HDL improve insulin sensitivity in 
humans, and whether it involves anti-inflammatory effects as we have now 
demonstrated in C57BL/6 mice, remains to be investigated.  
In summary, our findings that apoAI can improve insulin sensitivity through 
anti-inflammatory effects in hepatocytes may lead to novel approaches for the 
treatment of insulin resistance. We have shown that apoAI as a component of rHDLs 
potently suppresses the key mediator of inflammation, NF-κB, and in doing so can 
decrease the hepatic inflammation that underlies the onset of insulin resistance. HDL 
cholesterol levels are often reduced as a consequence of insulin resistance (13, 34).  The 
results from this study, therefore, have important therapeutic implications whereby 
raising HDL levels have the potential to protect against hepatic inflammation, and 
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Fig. 1: Body weights of C57BL/6 mice and hepatic mRNA levels of genes involved in fat 
synthesis. 
(A) Beginning at 6 weeks of age, C57BL/6 mice were fed a standard chow diet (StD) or high-
fat diet (HFD) for 16 wk. The HFD group was subdivided: HFD was administered endotoxin-
free PBS for the last 4 week of diet; HFD+2wk apoAI was administered apoAI for the last 2 
week of diet and HFD+4wk apoAI was administered apoAI for the last 4 week of diet. Body 
weight was monitored once weekly (n=10 for each treatment group). *p<0.001 vs. StD.  
(B) SREBP-1 and (C) ChREBP mRNA levels were measured by qPCR. mRNA levels were 
normalized to transcription factor IID (Tbp). Results are mean ± SEM (n=8-10). 
#
p< 0.05 vs. 
StD; *p<0.05 vs. HFD 
 
Fig. 2: Plasma glucose concentrations during metabolic assays in C57BL/6 mice fed a 
standard chow diet (StD) or a high fat diet (HFD) and treated with apoAI.  
(A) Intraperitoneal glucose tolerance test (IPGTT; glucose 1g /kg) and (B) area under the 
curve for glucose (AUC glucose) was calculated using the trapezoid rule. (C) Intraperitoneal 
insulin tolerance test (IPITT; insulin 0.75 IU/kg) and (D) AUC glucose. (E) Pyruvate 
(pyruvate 2 g/kg) challenge test and (F) AUC glucose.  Results are mean ± SEM (n=8-10). 
†p<0.05 vs. StD; *p< 0.05 vs. HFD.  
 
Fig. 3:  Serum cytokine levels in C57BL/6 mice treated with apoA-I.  
C57BL/6 mice were fed a standard chow diet (StD) or a high fat diet (HFD) and treated with 
apoAI as described in the methods. Circulating levels of TNF- (A), IL-6 (B) and IFN- (C) 
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were determined using the Bioplex kit (Bio-Rad). Results are mean ± SEM (n=8-10). †p< 
0.05 vs. StD; §p<0001 vs. StD; *p<0.05 vs. HFD; **p<0.01 vs. HFD. 
 
Fig. 4:  Administration of ApoAI decreases hepatic NF-B activity.  
C57BL/6 mice were fed a standard chow diet (StD) or a high fat diet (HFD) and treated with 
apoAI as described in the methods. Hepatic NF-B activity was measured by an 
oligonucleotide specific for the NF-B consensus DNA sequence. Results are means ± SEM 
(n=8-10). †p< 0.05 vs. StD; *p<0.05 vs. HFD. 
 
Fig. 5: rHDLs suppress TNF-activated signalling through the classical NF-B 
pathway.   
(A) HuH-7 cells transfected with an NF-B-luciferase reporter vector. Transfected cells were 
treated with PBS (control), TNF-, pre-incubated with rHDLs (final apoAI concentration 16 
mol/l or 0.45 mg/ml) then stimulated with TNF- (rHDL+TNF) or pre-incubated with 
rHDLs for 16 hrs, and the rHDLs removed from the culture media prior to activation with 
TNF- (rHDL//TNF). Cells were then harvested, lysed and the cell lysates were assayed for 
luciferase activity. Results are expressed as mean  SEM (n=5). §p<0.001 vs. Control; 
***p<0.001 vs. TNF-. 
(B) rHDLs suppress TNF-induced translocation of NF-B in hepatocytes. HuH-7 cells were 
treated with PBS (control), TNF or pre-incubated with rHDLs (final apoAI concentration 16 
mol/l or 0.45 mg/ml) then stimulated with TNF- (rHDL+TNF). Nuclear proteins were 
extracted and NF-B levels measured. Results are expressed as mean  SEM (n=5). †p<0.05 
vs. Control; ***p < 0.001 vs. TNF-. 
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(C) rHDLs suppress TNF--activated IKK activity in hepatocytes. HuH-7 cells were pre-
treated with rHDLs (final apoAI concentration 16 mol/l or 0.45 mg/ml) or PBS (control) for 
16 hrs then exposed to TNF for 15 mins. Results are expressed as mean  SEM (n=5). 
‡p<0.01 vs. Control; *p<0.05 vs. TNF-. 
(D) rHDLs prevent degradation of IB in hepatocytes. HuH-7 cells were pre-incubated for 
16 hrs with rHDLs (final apoAI concentration 16 mol/l or 0.45 mg/ml) or PBS (control) 
then stimulated with TNF- for 24 hours. Protein lysates were extracted and the level of 
phosphorylated IB measured by ELISA. Results are expressed as mean  SEM (n=5). 
§p<0.001 vs. Control; ***p<0.001 vs. TNF-. 
 
Fig. 6: Cholesterol depletion/repletion has no effect on the activation of NF-B. 
Cholesterol depletion was performed on HuH-7 cells by incubation with 1.5% cyclodextrin 
(CD) for 1 hour. Cholesterol repletion was performed by the addition of CD plus cholesterol 
for a further 1 hour. To assess the effects of rHDL on cholesterol mobilisaton, cells were 
treated with rHDL (final apoAI concentration 16 μmol/l or 0.45 mg/ml) for 16 hours 
followed by the addition of CD plus cholesterol for a further 1 hour. Following incubations, 
nuclear proteins were extracted and NF-B levels measured. Results are expressed as mean  
SEM (n=3).  
 
Fig. 7: Inhibition of TNF-induced NF-B activity by rHDLs versus salicylate. 
(A) HuH-7 cells were transfected with an NF-B-luciferase reporter vector then pre-
incubated for 16 hrs with PBS (control), rHDLs (final apoAI concentration 16 mol/l or 0.45 
mg/ml), sodium salicylate (5 mmol/l) or the IKK inhibitor, Wedelolactone, prior to 
stimulation with TNF- for 5 hours. The cells were harvested, lysed and the cell lysates were 
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assayed for luciferase activity. Results are expressed as mean  SEM (n=5). †p<0.05 vs. 
Control; *p<0.05 vs. TNF-. 
(B) HuH-7 cells were pre-incubated for 16 hrs with PBS (control), rHDLs (final apoAI 
concentration 16 mol/l or 0.45 mg/ml) or salicylate (S, 5 mmol/l) for 40 hours. Cell viability 
was then measured by the lactate dehydrogenase assay. Results are expressed as mean  SEM 







ELECTRONIC SUPPLEMENTARY MATERIAL FIGURE LEGENDS 
ESM Fig. I: Insulin resistance in C57BL/6 mice treated with apoAI  
HOMA-IR, homeostasis model assessment-insulin resistance  
(fasting glucose (mmol/l) x fasting insulin (mU/L)/22.5). Results are mean ± SEM (n=8-10). 
†p<0.05 vs. StD; *p<0.05 vs. HFD 
 
ESM Fig. II: Fasting blood glucose and serum insulin levels  
C57BL/6 mice were fed a standard chow diet (StD) or a high fat diet (HFD) and treated with 
apoAI as described in the method section. Following an overnight fast, (A) serum insulin 
levels were determined by ELISA and (B) blood glucose levels were determined using a 
glucose meter. n=8-10 for each treatment group. †p<0.05 vs. StD; *p<0.05 vs. HFD 
 
ESM Fig. III: Circulating triglyceride and hepatic neutral lipid (triglyceride and 
cholesterol esters) levels.  
C57BL/6 mice were fed a standard chow diet (StD) or a high fat diet (HFD) and treated with 
apoAI as described in the method section. (A) Serum triglyceride levels were determined as 
described in the method section. (B) Intrahepatic neutral lipid (triglyceride plus cholesterol 
esters) accumulation was determined by Oil Red-O staining. n=8-10 for each treatment 
group. ‡p<0.01 vs. StD; *p<0.05 vs. HFD. 
 
ESM Fig. IV: ApoAI does not affect hepatic expression of DHCR24 mRNA levels.  
C57BL/6 mice were fed a standard chow diet (StD) or a high fat diet (HFD) and treated with 
apoAI as described in the method section. DHCR24 mRNA levels were measured by qPCR. 




ESM Fig. V: AI-rHDLs suppress TNF-activated NF-B target gene expression in 
HuH-7 cells.  
HuH-7 cells were pre-incubated with AI-rHDLs (final apoAI concentration, 16 µmol/l or 
0.45 mg/ml) or PBS (vehicle control) for 16 hrs then stimulated with TNF for 5 hrs.   (A) 
Representative macroarray images for PBS+TNF and rHDL+TNF treatments are shown. 
(B) Schematic diagram of the Human TranSignal NF-B Target Gene Array (Panomics). The 
genes on the array are spotted in duplicate. For alignment purpose, biotinylated DNA has 





Table 1: Hepatic mRNA gene expression.  
Beginning at 6 weeks of age, C57BL/6 mice were fed a standard chow (StD) or high-fat diet 
for 16 wk. The HFD group were divided into 3 groups and administered with apoAI (8 
mg/kg) for 4 wk, 2 wk or endotoxin-free PBS (HFD). Total RNA was isolated from liver 
tissue and mRNA levels measured by RT-qPCR. All cytokine mRNA levels were normalised 
to transcription factor IID (Tbp). RT-qPCR data represent fold increase over StD or HFD. 





Encoded protein  HFD/StD      2 wk apoAI/HFD 4 wk apoAI/HFD 
PEPCK 1.95 ± 1.94* 0.43 ± 0.57* 0.45 ± 0.70* 
G6Pase 1.76 ± 3.10* 0.54 ± 0.84* 0.41 ± 0.53** 
TNF-α 1.65 ± 4.00* 0.11 ± 0.10** 0.22 ± 0.17** 
IL-6 1.33 ± 2.20* 0.49 ± 1.17** 0.30 ± 0.70** 
IFN- 4.14 ± 3.10** 0.70 ± 0.66* 0.61 ± 1.00** 
IL-1β 4.96 ± 6.11* 0.42 ± 0.25** 0.24 ± 0.19** 
SAA1 21.06 ± 8.38** 0.51 ± 0.36* 0.25 ± 0.28** 
CD68 4.43 ± 1.76** 0.64 ± 1.89* 0.58 ± 1.06* 
F4/80 7.02 ± 5.87** 0.63 ± 1.46* 0.58 ± 0.99* 
* 
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 PBS + TNFa rHDL + TNFa 
A 
B 
 Gene Accession no. Forward Reverse 
A1AT NM_001002236 CAATGCCACCGCCATCTTCTTC CAGTTGACCCAGGACGCTCTT 
GAL3 NR_003225 CCTTCCACTTTAACCCACGCTTC ACCGACTGTCTTTCTTCCCTTCC 
GRO1 NM_001511 TGCTGCTCCTGCTCCTGGTA GTGTGGCTATGACTTCGGTTTGG 
GSTP1 NM_000852 TCGCCGCCGCAGTCTTC GTCACCACCTCCTCCTTCCAG 
IGFBP2 NM_000597 GGGAGTGCTGGTGTGTGAAC CGGCTGGCTGCGGTCTA 
1L8 NM_000584 CGGAAGGAACCATCTCACTGT GGTCCACTCTCAATCACTCTCA 
LAMB2 NM_002292 TGTGATTGTGACTCTCGTGGAAT CAGGGATGGCAGGCAGGAA 
MAD3 NM_031300 GCTGGAGGTGGATGTGGAGAG GGCACGAGTAGAGGGCAGAG 
MCP1 NM_002982 CAA TCA ATG CCC CAG TCA C GAT TCT TGG GTT GTG GGA GTG 
MNSOD NM_001024465 CCTAACGGTGGTGGAGAAC AACCTGAGCCTTGGACAC 
TP53 NM_000546 GCATCTACAAGCAGTCACAGC TCCACACGCAAATTTCCTTCC 
PRG1 NM_003897 GCATCCTCCAGCATCTCAACTC CTACCTCGCAGCCACCCTAAA 
PTX3 NM_002852 GTGGGTGGTGGCTTTGATGAAA GATGTGACAAGACTCTGCTCCTC 
B2M BC064910.1 CATCCAGCGTACTCCAAAGA GACAAGTCTGAATGCTCCAC 
SAA1 NM_000331 CCAATCACTTCCGACCTGCTG GCTTTGTATCCCTGCCCTGAG 
CHREBP NM_021455.4  CTG GGG ACC TAA ACA GGA GC GAA GCC ACC CTA TAG CTC CC 
PEPCK NM_011044.2 GGTGTTTACTGGGAAGGCATC CAATAATGGGGCACTGGCTG 
G6P NM_008061.3 CATGGGCGCAGCAGGTGTATACT CAAGGTAGATCCGGGACAGACAG 
TNFα BC137720.1 CTGTGAAGGGAATGGGTGTT CTCCCTTTGCAGAACTCAGG 
IL6 DQ788722.1 TGTGCAATGGCAATTCTGAT GGAAATTGGGGTAGGAAGGA 
IFN BC119065.1 GAAAAGGAGTCGCTGCTGAT CGCAATCACAGTCTTGGCTA 
IL1β M15131.1 GCTCAGGGTCACAAGAAACC CATCAAAGCAATGTGCTGGT 
CD68 BC021637.1 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
F4/80 X93328.1 CTCCAAGCCTATTATCTATACC CTTCCACAATCTCACAGC 
SREBP1 NM_011480.3 TTTCCTTAACGTGGGCCTAGTC TGTCTTCGATGTCGTTCAAAACC 
DHCR24 NM_053272.2 GAAGTCAACGCAAGCCTCTCC ACATCGCCACACCCATCCC 
TBP U63933.1 GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
 
